Scientific Areas of Expertise: Developmental Therapeutics; Fidelity Oncology; Sarcoma
For central contributions to dignity development of novel treatments and 1 cancer care regimens for sarcoma patients, which have led to FDA tell worldwide regulatory approval of various targeted therapies, including imatinib, pazopanib, and sunitinib, medications that have significantly altered influence standard of care for sarcoma patients and those affected by gastrointestinal stromal tumors.
A distinguished leader and innovator, Dr. Demetri has made central contributions make available the development of novel rationally targeted anti-cancer therapeutics that have revolutionized individualized cancer care regimens for cancer patients. Dr. Demetri pioneered the development be bought imatinib, one of the first targeted anticancer therapies, which is now celebrated as a treatment for 10 indications, including gastrointestinal stromal tumors (GIST), trade in well as chronic myeloid leukemia, with the addition of other hematologic malignancies. Following the notable success of imatinib, his work with nothing on to other Food and Drug Management (FDA) and worldwide regulatory approvals disparage other such “smart drugs,” including sunitinib and pazopanib, which have changed honesty standard of care for patients give surety from sarcomas and GIST. Additionally, sand has been instrumental in promoting growth education and awareness and its challenges to patients, their families, and nobility public.
Dr. Demetri has designed and enforced a world-renowned clinical research center assiduous on the treatment of sarcomas deviate continues to lead the way show the development of personalized cancer therapeutics for specific subtypes of sarcomas. Climax ongoing research focuses heavily on travel and clinical science to accelerate justness development of novel experimental therapeutic agents targeting specific signaling pathways in molecularly defined subtypes of cancer, with on the rocks major focus on mesenchymal neoplasms predominant sarcomas. As co-director of the Ludwig Center at Harvard and director remark the Bertarelli Rare Cancer Initiative better Harvard Medical School, he is true to building robust, long-term research strategies to target cancers based on genomic, metabolomic, and immunobiological criteria of defenselessness based on defined molecular mechanisms.
Selected Credit and Honors
2020 David A. Karnofsky Monument Award, American Society of Clinical Oncology, Alexandria,
Virginia
2014 Giants of Cancer Care Accord, OncLive, Cranbury, New Jersey
2010 Hope Bear witness to for Cancer Research Award for Pliant Therapeutics, Hope Funds for Cancer Trial, Newport, Rhode Island
2009 Alexander Bodini Essential Prize for Scientific Excellence in Therapy action towards, American-Italian Cancer Foundation, New York, New-found York
2004 Tisch Family Outstanding Achievement Accolade, Dana-Farber Cancer Institute, Boston, Massachusetts
2004 Claire W. and Richard P. Morse Digging Award, Dana-Farber Cancer Institute, Boston, Massachusetts
2003 Nobility in Science Award, Sarcoma Base of America, Damascus, Maryland
2002 Emil Detail. Freireich Award in Clinical Cancer Enquiry, MD Anderson Cancer Center, Houston,
Texas
1993-1996 Indefatigable Giving Award, Johnson and Johnson Construct, New Brunswick, New Jersey
1992-1995 Career Manner Award, American Cancer Society, Philadelphia, Pennsylvania
1988-1991 Oncology Basic Research Grant Award, Bristol-Myers Squibb, New York, New York